The demographic characteristics of Medicaid-eligible uninsured children

S Avruch1, S Machlin, P Bonin

  • 1US General Accounting Office, Washington, DC 20548, USA.

Insights

In 1993, over 2.3 million children eligible for Medicaid remained uninsured. These children were more likely to have working parents and included higher proportions of young children, those in single-parent homes, and minority children.

Area of Science:

  • Health Services Research
  • Pediatric Health Policy
  • Health Economics

Background:

  • Medicaid is a crucial public health insurance program for low-income children in the United States.
  • Despite eligibility, a significant number of children remain uninsured, highlighting gaps in program access and enrollment.

Purpose of the Study:

  • To estimate the number of uninsured children in 1993 who were eligible for Medicaid.
  • To identify demographic and socioeconomic characteristics of uninsured, Medicaid-eligible children.

Main Methods:

  • Analysis of data from the March 1990 and 1994 Current Population Surveys.
  • Estimation of the uninsured population among children eligible for Medicaid.

Main Results:

  • At least 2.3 million children eligible for Medicaid were uninsured in 1993.
  • Uninsured, Medicaid-eligible children were more likely to have working parents compared to children enrolled in Medicaid.
  • Higher proportions of uninsured children eligible for Medicaid were under age 6, lived in female-headed single-parent families, and were African-American or Hispanic.

Conclusions:

  • A substantial number of children eligible for Medicaid do not enroll in the program.
  • Uninsured, eligible children exhibit distinct characteristics compared to those enrolled in Medicaid, suggesting targeted outreach is needed.
Abstract

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...